A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema
An Open-label, Randomized Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneous Administration of Human Plasma-derived C1-esterase Inhibitor in the Prophylactic Treatment of Hereditary Angioedema
Sponsor: CSL Behring
Listed as NCT02316353, this PHASE3 trial focuses on Hereditary Angioedema Types I and II and remains completed. Sponsored by CSL Behring, it has been updated 14 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE3
▶ Show 9 earlier versions
-
Dec 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Dec 2018 [monthly]
Completed PHASE3
-
Apr 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Nov 2017 — Apr 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Oct 2017 — Nov 2017 [monthly]
Active Not Recruiting PHASE3
-
Sep 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE3
-
Jun 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Dec 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CSL Behring
For direct contact, visit the study record on ClinicalTrials.gov .